A study to explore the efficacy of 0.05% CSA eye drops in the treatment of chronic ocular graft-versus-host disease

To explore the efficacy and safety of 0.05% CSA eye drops in chronic ocular graft-versus-host disease

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100054899

Enrollment

Unknown

Registered

2021-12-29

Start date

2021-01-01

Completion date

Unknown

Last updated

2022-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graft-versus-host disease

Interventions

0.05% cyclosporine treatment group:Treatment with 0.05% cyclosporine

0.1% tacrolimus treatment group:Treatment with 0.1% tacrolimus

Eligibility

Sex/Gender

All

Age

15 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients meeting the diagnostic criteria of NIH chronic ocular GVHD; 2. Non pregnant patients aged 15-60 years; 3. Had not previously received topical immunosuppressive treatment of the eye.

Exclusion criteria

Exclusion criteria: 1. Patients with incomplete clinical data or lost to follow-up due to forced factors; 2. Patients who are forced to receive other related treatment due to severe infection, allergy or other immune disease-related symptoms.

Design outcomes

Primary

Measure	Time frame
Visual acuity;Intraocular pressure;Ocular Surface Disease Index;Corneal fluorescein staining;Tear break-up time;Tear meniscus;Schirmer's test;	—

Countries

China

Contacts

Public ContactHong Jing

Peking University Third Hospital

hongjing1964@sina.com+86 13910573646

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026